NCT06361888 - A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

552

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine

"Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Camrelizumab: 200mg, IV drip, Q3W, D1~3. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~4. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"

DRUG

Nab-paclitaxel Plus Gemcitabine

"Drug: Nab-paclitaxel Plus Gemcitabine~1. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~2. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"

DRUG

Surufatinib with Nab-paclitaxel, and Gemcitabine

"Drug: Surufatinib with Nab-paclitaxel, and Gemcitabine~1. Surufatinib: 250mg or 200mg, qd~2. Nab-paclitaxel: 125 mg/m2, IV drip, D1,D8~3. Gemcitabine : 1000 mg/m2, IV drip, D1, D8"

Trial Locations (2)

210000

NOT_YET_RECRUITING

Nanjing Tianyinshan Hospital, Nanjing

300000

RECRUITING

Tianjin Cancer Hospital, Tianjin